Avalo Therapeutics Inc (AVTX) Actualités

Form 8-K - Current report

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the...

Avalo Therapeutics to Present at Upcoming Investor Conferences

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form S-8 - Securities to be offered to employees in employee benefit plans

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with...

Form 8-K - Current report

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Global study in approximately 180 adults with hidradenitis suppurativa to assess the efficacy and safety of two...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report